Nanoliposomal Irinotecan for Use in Treating Small Cell Lung Cancer
AssigneeIpsen Biopharm Ltd.
InventorsBambang Adiwijaya, Jonathan Basil Fitzgerald, Helen Lee
Life of this patent
Estimating the term…
Abstract
Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.
Claims20
A method of treating a human patient diagnosed with small cell lung cancer (SCLC) following disease progression on or after first-line platinum-based therapy for the SCLC, the method comprising administering to the human patient an antineoplastic therapy once every two weeks, the antineoplastic therapy consisting of a 70 mg/m2 (free base) dose of liposomal irinotecan.
A method of treating a human patient who is not homozygous for the UTG1A1*28 allele and is diagnosed with small cell lung cancer (SCLC) following disease progression on or after first-line platinum-based therapy for the SCLC, the method comprising administering to the human patient an antineoplastic therapy once every two weeks in a six-week cycle, the antineoplastic therapy consisting of a 70 mg/m2 (free base) dose of liposomal irinotecan.
A method of treating a human patient diagnosed with small cell lung cancer (SCLC) following disease progression on or after a first-line platinum-based therapy for the SCLC selected from the group consisting of cisplatin or carboplatin, the method comprising administering to the human patient an antineoplastic therapy once every two weeks for a total of at least three six-week cycles, the antineoplastic therapy consisting of a 70 mg/m2 (free base) dose of liposomal irinotecan;
- wherein the human patient is not homozygous for the UTG1A1*28 allele and has the following prior to the administration of each antineoplastic therapy of liposomal irinotecan:
- (a) a blood ANC greater than 1,500 cells/microliter without the use of hematopoietic growth factors;
- (b) a blood platelet count of greater than 100,000 cells per microliter;
- (c) a blood hemoglobin greater than 9 g/dL;
- and
- (d) a serum creatinine of less than or equal to 1.5×ULN and a creatinine clearance of greater than or equal to 40 mL/min.
Dependencies are inferred from the claim text.